Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade
This article was originally published in The Pink Sheet Daily
Policy changes since FDA's first biosimilar approval produce a label that is more clearly different than, but also more closely tied to, its brand reference.
You may also be interested in...
US FDA Again Looks Outside Generic Drugs Office For New Director
Sally Choe, who has been working in the Office of Translational Sciences, will take over for Kathleen Uhl in March.
US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?
Agency has scheduled only two advisory committee meetings in 2017; does it indicate the agency plans to conduct fewer meetings going forward?
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.